SARS-CoV 2 Clinical Trial
Official title:
Studies of Ongoing and Completed SARS-CoV-2 Infection (Which Causes COVID-19) Within the Healthcare in Stockholm County, With Regard to Vaccinations.
Verified date | October 2023 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To investigate the incidence of SARS-CoV-2 infections after vaccination, to monitor the development of SARS-CoV-2 antibody levels after vaccination and to compare this in relation to both previous health & disease, previous antibody responses and in relation to future disease occurring after vaccination.
Status | Active, not recruiting |
Enrollment | 10000 |
Est. completion date | December 31, 2024 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Study participant who agreed to be included in the study "Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County". - Study participant who has received or will receive vaccine against Covid-19 and who gives new written consent to the study "Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations". Exclusion Criteria: - those who have not given informed consent to participate in the study In this study, no initiative is taken for vaccination. The vaccinations are carried out by the healthcare system and of course follow the established exclusion and inclusion criteria for the approved vaccines. All persons who have received the vaccine and who give written consent are eligible to be included in the study. |
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Karolinska University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SARS-CoV-2 infection | Characterized by whether they are asymptomatic infections or sick leave-requiring infections. | 24 months post primary vaccination | |
Secondary | SARS-CoV-2 antibody induction | Antibodies will be characterized in terms of antibody levels, which SARS-CoV-2 antigen to which the response is directed and whether the antibodies are protective or not. | 24 months post primary vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Withdrawn |
NCT04386447 -
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
Phase 2 | |
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Completed |
NCT04615936 -
Nasal Photodisinfection COVID-19 Proof of Concept Study
|
N/A | |
Completed |
NCT04369794 -
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
|
Phase 4 | |
Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
Completed |
NCT04542850 -
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19
|
N/A | |
Completed |
NCT04382040 -
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
|
Phase 2 | |
Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
Completed |
NCT04378582 -
Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
|
||
Completed |
NCT04383587 -
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
|
N/A | |
Recruiting |
NCT04402814 -
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
|
||
Completed |
NCT04425889 -
COVID-19 Antibodies Among Healthcare Workers
|
||
Completed |
NCT04395924 -
Maternal-foetal Transmission of SARS-Cov-2
|
||
Completed |
NCT04374565 -
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
|
Phase 2 | |
Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|